Literature DB >> 3488022

In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus.

L P Elwell, H R Wilson, V B Knick, B R Keith.   

Abstract

The in vitro susceptibilities of 16 independent, geographically distinct clinical isolates of methicillin-resistant Staphylococcus aureus to trimethoprim (TMP) in combination with sulfamethoxazole (SMX) were evaluated. Although methicillin-resistant S. aureus strains appear to be universally resistant to SMX, the combination TMP-SMX was found to be synergistic in vitro (in combination, the MICs of both drugs decreased 6- to 25-fold) as well as in vivo (5- to 6-fold reduction in TMP at 50% effective doses).

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3488022      PMCID： PMC180506          DOI： 10.1128/AAC.29.6.1092

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Letter: Trimethoprim-sulfamethoxazole and bacterial meningitis.

Authors:  Z Farid; N I Girgis; W Yassin
Journal:  Ann Intern Med       Date:  1976-01       Impact factor: 25.391

2.  Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia.

Authors:  E Bengtsson; M Svanbom; G Tunevall
Journal:  Scand J Infect Dis       Date:  1974

3.  Antimicrobial synergism--an elusive concept.

Authors:  R C Moellering
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

4.  Treatment of meningitis and septicemia in infancy with a sulphamethoxazole/trimethorpim combination.

Authors:  K G Sabel; A Brandberg
Journal:  Acta Paediatr Scand       Date:  1975-01

5.  In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.

Authors:  M Foldes; R Munro; T C Sorrell; S Shanker; M Toohey
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

6.  Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis.

Authors:  M A Tamer; J D Bray
Journal:  Clin Pediatr (Phila)       Date:  1982-02       Impact factor: 1.168

7.  The emergence of methicillin-resistant Staphylococcus aureus.

Authors:  R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  Emergence of gentamicin- and methicillin-resistant Staphylococcus aureus strains in New York City hospitals.

Authors:  S Schaefler; D Jones; W Perry; L Ruvinskaya; T Baradet; E Mayr; M E Wilson
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

9.  Oral rifampin and trimethoprim/sulfamethoxazole therapy in asymptomatic carriers of methicillin-resistant Staphylococcus aureus infections.

Authors:  R T Ellison; F N Judson; L C Peterson; D L Cohn; J M Ehret
Journal:  West J Med       Date:  1984-05

10.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations.

Authors:  V Gopal; A L Bisno; F J Silverblatt
Journal:  JAMA       Date:  1976-10-04       Impact factor: 56.272
  10 in total
  10 in total

Review 1.  Methicillin-resistant staphylococci: detection methods and treatment of infections.

Authors:  C J Hackbarth; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 2.  Methicillin-resistant staphylococci.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Surgical debridement with retention of spinal instrumentation and long-term antimicrobial therapy for multidrug-resistant surgical site infections after spinal surgery: a case series.

Authors:  Shingo Miyazaki; Kenichiro Kakutani; Koichiro Maeno; Toru Takada; Takashi Yurube; Masahiro Kurosaka; Kotaro Nishida
Journal:  Int Orthop       Date:  2015-12-21       Impact factor: 3.075

4.  Management of Staphylococcus Mediated Systemic Infection by Enhancing the Resurging Activity of Co-trimoxazole in Presence of Cryptdin-2.

Authors:  Amrita Kaur; Shiv Kumar Chabba; Ujjwal Jit Kaur; Arashdeep Kaur; Simran Preet; Praveen Rishi
Journal:  Indian J Microbiol       Date:  2017-09-09       Impact factor: 2.461

5.  Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.

Authors:  M de Górgolas; P Avilés; C Verdejo; M L Fernández Guerrero
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

6.  Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis.

Authors:  G Euba; O Murillo; N Fernández-Sabé; J Mascaró; J Cabo; A Pérez; F Tubau; R Verdaguer; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

7.  Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.

Authors:  Mical Paul; Jihad Bishara; Dafna Yahav; Elad Goldberg; Ami Neuberger; Nesrin Ghanem-Zoubi; Yaakov Dickstein; William Nseir; Michael Dan; Leonard Leibovici
Journal:  BMJ       Date:  2015-05-14

8.  RexAB is essential for the mutagenic repair of Staphylococcus aureus DNA damage caused by co-trimoxazole.

Authors:  Rebecca S Clarke; Maya S Bruderer; Kam Pou Ha; Andrew M Edwards
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

9.  Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997.

Authors:  Jihad Bishara; Silvio Pitlik; Zmira Samra; Itzhak Levy; Mical Paul; Leonard Leibovici
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

10.  Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs).

Authors:  Laurene Deconinck; Aurélien Dinh; Christophe Nich; Thomas Tritz; Morgan Matt; Olivia Senard; Simon Bessis; Thomas Bauer; Martin Rottman; Jérome Salomon; Frédérique Bouchand; Benjamin Davido
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.